Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy

Source :: Business Wire. November 21, 2022
Publication Year :: 2022
Abstract: * Prothena is eligible to receive development and sales milestone payments from Novo Nordisk totaling up to $1.2 billion, including $100 million announced to date * PRX004/NNC6019 continues to advance [...]

Subjects :: Novo Nordisk A/S -- Investigations
Heart diseases -- Investigations
Medical research -- Investigations
Medicine, Experimental -- Investigations
Homeopathy -- Materia medica and therapeutics
Therapeutics -- Investigations
Cardiomyopathy -- Investigations
Company legal issue
Business
Business, international

Tools